Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 4 minute read Pharma Industry News Neurocrine Biosciences’ one-year CAHtalyst phase 3 data shows sustained weight and insulin-resistance benefits in CAH patients Neurocrine Biosciences’ CRENESSITY Phase 3 data shows strong weight and metabolic benefits in CAH—see what this means for NBIX stock and future sales. byPallavi MadhirajuJuly 15, 2025